NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO – Get Free Report) shares were up 2.6% on Wednesday . The company traded as high as $3.50 and last traded at $3.10. Approximately 39,253 shares were traded during mid-day trading, a decline of 96% from the average daily volume of 1,065,755 shares. The stock had previously closed at $3.02.
NeuroBo Pharmaceuticals Price Performance
The business’s 50 day moving average is $4.43 and its two-hundred day moving average is $3.96.
About NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals, Inc, a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity.
Read More
- Five stocks we like better than NeuroBo Pharmaceuticals
- Investing In Automotive Stocks
- 3 Stocks Leading the U.S. Agriculture Comeback
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- How to Use Put Debit Spreads to Profit From Falling Stocks
- 10 Best Airline Stocks to Buy
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for NeuroBo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroBo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.